Entrada Therapeutics, Inc. Financials
This page shows Entrada Therapeutics, Inc. (TRDA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Entrada Therapeutics, Inc. has an operating margin of -621.1%, meaning the company retains $-621 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from 22.3% the prior year.
Entrada Therapeutics, Inc.'s revenue declined 87.9% year-over-year, from $210.8M to $25.4M. This contraction results in a growth score of 0/100.
Entrada Therapeutics, Inc. carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 12.53, Entrada Therapeutics, Inc. holds $12.53 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Entrada Therapeutics, Inc. generated -$128.5M in operating cash flow, capex of $1.0M consumed most of it, leaving -$129.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Entrada Therapeutics, Inc. generates a -47.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from 15.3% the prior year.
Entrada Therapeutics, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Entrada Therapeutics, Inc. generates $0.89 in operating cash flow (-$128.5M OCF vs -$143.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Entrada Therapeutics, Inc. generated $25.4M in revenue in fiscal year 2025. This represents a decrease of 87.9% from the prior year.
Entrada Therapeutics, Inc.'s EBITDA was -$153.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 402.9% from the prior year.
Entrada Therapeutics, Inc. reported -$143.8M in net income in fiscal year 2025. This represents a decrease of 319.0% from the prior year.
Entrada Therapeutics, Inc. earned $-3.47 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 306.5% from the prior year.
Cash & Balance Sheet
Entrada Therapeutics, Inc. generated -$129.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 189.7% from the prior year.
Entrada Therapeutics, Inc. held $90.4M in cash against $0 in long-term debt as of fiscal year 2025.
Entrada Therapeutics, Inc. had 38M shares outstanding in fiscal year 2025. This represents an increase of 1.9% from the prior year.
Margins & Returns
Entrada Therapeutics, Inc.'s operating margin was -621.1% in fiscal year 2025, reflecting core business profitability. This is down 643.4 percentage points from the prior year.
Entrada Therapeutics, Inc.'s net profit margin was -565.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 596.6 percentage points from the prior year.
Entrada Therapeutics, Inc.'s ROE was -47.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 62.3 percentage points from the prior year.
Capital Allocation
Entrada Therapeutics, Inc. invested $142.3M in research and development in fiscal year 2025. This represents an increase of 13.5% from the prior year.
Entrada Therapeutics, Inc. invested $1.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 67.0% from the prior year.
TRDA Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M-19.5% | $1.6M-17.2% | $1.9M-90.5% | $20.6M-45.0% | $37.4M+91.1% | $19.6M-79.3% | $94.7M+60.2% | $59.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $34.0M-11.5% | $38.4M+1.3% | $37.9M+18.1% | $32.1M-4.0% | $33.4M+6.9% | $31.3M-2.4% | $32.0M+12.0% | $28.6M |
| SG&A Expenses | $9.6M-7.3% | $10.3M-5.7% | $10.9M+6.3% | $10.3M+4.2% | $9.9M-1.1% | $10.0M+8.0% | $9.2M-1.7% | $9.4M |
| Operating Income | -$42.2M+10.3% | -$47.1M-0.4% | -$46.8M-115.0% | -$21.8M-271.4% | -$5.9M+72.9% | -$21.7M-140.5% | $53.4M+153.0% | $21.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $92K-85.9% | $654K+267.4% | $178K | $0+100.0% | -$1.9M-0.5% | -$1.9M-167.4% | $2.8M+50.6% | $1.8M |
| Net Income | -$39.2M+11.3% | -$44.1M-2.4% | -$43.1M-148.4% | -$17.3M-1634.0% | $1.1M+108.1% | -$14.0M-125.5% | $55.0M+134.2% | $23.5M |
| EPS (Diluted) | N/A | $-1.06-1.9% | $-1.04-147.6% | $-0.42 | N/A | $-0.35-122.6% | $1.55+127.9% | $0.68 |
TRDA Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $377.4M-8.6% | $412.9M-8.0% | $448.8M-7.7% | $486.5M-7.6% | $526.3M-5.1% | $554.6M-4.7% | $582.0M+13.9% | $510.8M |
| Current Assets | $306.3M-9.5% | $338.3M-8.4% | $369.1M-8.4% | $403.2M-8.4% | $440.0M-5.4% | $465.3M-4.9% | $489.5M+18.2% | $414.2M |
| Cash & Equivalents | $90.4M-3.1% | $93.3M+28.7% | $72.5M+6.8% | $67.8M-33.0% | $101.2M+29.7% | $78.0M-57.9% | $185.3M+170.7% | $68.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $71.2M-1.3% | $72.2M+4.2% | $69.3M+0.1% | $69.2M-29.1% | $97.6M-26.1% | $132.1M-13.1% | $152.0M-37.0% | $241.5M |
| Current Liabilities | $24.5M+1.8% | $24.0M+21.3% | $19.8M+7.4% | $18.4M-53.3% | $39.5M-44.1% | $70.6M-17.7% | $85.8M-50.7% | $173.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $306.1M-10.2% | $340.7M-10.2% | $379.5M-9.0% | $417.3M-2.7% | $428.7M+1.5% | $422.4M-1.7% | $429.9M+59.6% | $269.4M |
| Retained Earnings | -$273.1M-16.7% | -$233.9M-23.3% | -$189.8M-29.4% | -$146.7M-13.4% | -$129.3M+0.9% | -$130.5M-12.1% | -$116.4M+32.1% | -$171.5M |
TRDA Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$32.2M-13.7% | -$28.3M+4.0% | -$29.5M+23.4% | -$38.5M-21.8% | -$31.6M-30.2% | -$24.3M-160.9% | $39.8M+256.1% | -$25.5M |
| Capital Expenditures | -$207K-21.1% | -$171K-162.2% | $275K-76.0% | $1.1M+80.2% | $635K-0.6% | $639K-38.9% | $1.0M+24.8% | $838K |
| Free Cash Flow | -$32.4M-13.8% | -$28.5M+4.3% | -$29.8M+24.9% | -$39.7M-23.0% | -$32.2M-29.5% | -$24.9M-164.2% | $38.8M+247.2% | -$26.4M |
| Investing Cash Flow | $29.1M-40.7% | $49.1M+45.3% | $33.8M+606.6% | $4.8M-91.0% | $53.4M+164.4% | -$82.9M-240.1% | -$24.4M-193.3% | $26.1M |
| Financing Cash Flow | $192K+2300.0% | $8K-97.6% | $337K-3.7% | $350K-75.0% | $1.4M+12845.5% | -$11K-100.0% | $101.4M+49107.3% | $206K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TRDA Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -3249.3%-334.1pp | -2915.2%-512.7pp | -2402.5%-2296.5pp | -106.0%-90.3pp | -15.7%+95.0pp | -110.7%-167.1pp | 56.4%+20.7pp | 35.7% |
| Net Margin | -3014.9%-280.5pp | -2734.4%-524.0pp | -2210.4%-2126.0pp | -84.4%-87.4pp | 3.0%+74.7pp | -71.7%-129.8pp | 58.1%+18.4pp | 39.7% |
| Return on Equity | -12.8%+0.2pp | -13.0%-1.6pp | -11.4%-7.2pp | -4.2%-4.4pp | 0.3%+3.6pp | -3.3%-16.1pp | 12.8%+4.1pp | 8.7% |
| Return on Assets | -10.4%+0.3pp | -10.7%-1.1pp | -9.6%-6.0pp | -3.6%-3.8pp | 0.2%+2.7pp | -2.5%-12.0pp | 9.5%+4.9pp | 4.6% |
| Current Ratio | 12.53-1.6 | 14.08-4.6 | 18.64-3.2 | 21.88+10.7 | 11.15+4.6 | 6.59+0.9 | 5.70+3.3 | 2.38 |
| Debt-to-Equity | 0.23+0.0 | 0.21+0.0 | 0.18+0.0 | 0.17-0.1 | 0.23-0.1 | 0.31-0.0 | 0.35-0.5 | 0.90 |
| FCF Margin | -2495.0%-730.2pp | -1764.8%-238.4pp | -1526.4%-1333.5pp | -192.9%-106.7pp | -86.2%+41.0pp | -127.3%-168.2pp | 41.0%+85.5pp | -44.6% |
Similar Companies
Frequently Asked Questions
What is Entrada Therapeutics, Inc.'s annual revenue?
Entrada Therapeutics, Inc. (TRDA) reported $25.4M in total revenue for fiscal year 2025. This represents a -87.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Entrada Therapeutics, Inc.'s revenue growing?
Entrada Therapeutics, Inc. (TRDA) revenue declined by 87.9% year-over-year, from $210.8M to $25.4M in fiscal year 2025.
Is Entrada Therapeutics, Inc. profitable?
No, Entrada Therapeutics, Inc. (TRDA) reported a net income of -$143.8M in fiscal year 2025, with a net profit margin of -565.5%.
What is Entrada Therapeutics, Inc.'s EBITDA?
Entrada Therapeutics, Inc. (TRDA) had EBITDA of -$153.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Entrada Therapeutics, Inc.'s operating margin?
Entrada Therapeutics, Inc. (TRDA) had an operating margin of -621.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Entrada Therapeutics, Inc.'s net profit margin?
Entrada Therapeutics, Inc. (TRDA) had a net profit margin of -565.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Entrada Therapeutics, Inc.'s return on equity (ROE)?
Entrada Therapeutics, Inc. (TRDA) has a return on equity of -47.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Entrada Therapeutics, Inc.'s free cash flow?
Entrada Therapeutics, Inc. (TRDA) generated -$129.6M in free cash flow during fiscal year 2025. This represents a -189.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Entrada Therapeutics, Inc.'s operating cash flow?
Entrada Therapeutics, Inc. (TRDA) generated -$128.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Entrada Therapeutics, Inc.'s total assets?
Entrada Therapeutics, Inc. (TRDA) had $377.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Entrada Therapeutics, Inc.'s capital expenditures?
Entrada Therapeutics, Inc. (TRDA) invested $1.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Entrada Therapeutics, Inc. spend on research and development?
Entrada Therapeutics, Inc. (TRDA) invested $142.3M in research and development during fiscal year 2025.
What is Entrada Therapeutics, Inc.'s current ratio?
Entrada Therapeutics, Inc. (TRDA) had a current ratio of 12.53 as of fiscal year 2025, which is generally considered healthy.
What is Entrada Therapeutics, Inc.'s debt-to-equity ratio?
Entrada Therapeutics, Inc. (TRDA) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Entrada Therapeutics, Inc.'s return on assets (ROA)?
Entrada Therapeutics, Inc. (TRDA) had a return on assets of -38.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Entrada Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Entrada Therapeutics, Inc. (TRDA) had $90.4M in cash against an annual operating cash burn of $128.5M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Entrada Therapeutics, Inc.'s Piotroski F-Score?
Entrada Therapeutics, Inc. (TRDA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Entrada Therapeutics, Inc.'s earnings high quality?
Entrada Therapeutics, Inc. (TRDA) has an earnings quality ratio of 0.89x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Entrada Therapeutics, Inc.?
Entrada Therapeutics, Inc. (TRDA) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.